These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25100024)

  • 1. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
    Luo F; Gu J; Chen L; Xu X
    Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
    Ryu S; Imai YN; Oiki S
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3848-51. PubMed ID: 23711922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.
    Negami T; Araki M; Okuno Y; Terada T
    Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer simulations of structure-activity relationships for HERG channel blockers.
    Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
    Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
    Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
    Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
    Masetti M; Cavalli A; Recanatini M
    J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
    Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the cardiotoxicity of N-n-butyl haloperidol iodide: Inhibition mechanisms on hERG channels.
    Liao J; Yang Z; Yang J; Lin H; Chen B; Fu H; Lin X; Lu B; Gao F
    Toxicology; 2024 Nov; 508():153916. PubMed ID: 39128488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
    Zünkler BJ; Claassen S; Wos-Maganga M; Rustenbeck I; Holzgrabe U
    Toxicology; 2006 Dec; 228(2-3):239-48. PubMed ID: 17027138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
    Hancox JC; James AF
    Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of HERG channel block by clofilium and ibutilide.
    Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
    Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
    Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
    Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
    Park SJ; Kim KS; Kim EJ
    J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods.
    Osterberg F; Aqvist J
    FEBS Lett; 2005 May; 579(13):2939-44. PubMed ID: 15893317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.